CRISPR’s Bold Bet: One Shot to Disrupt Cholesterol Care

CTX310 shows up to 86% LDL reduction in early trial, with full results expected in 2025

28 Jun 2025

CRISPR Therapeutics has reported early trial results suggesting its experimental gene-editing therapy could one day replace long-term cholesterol treatment.

The therapy, CTX310, is designed as a one-time intervention to permanently lower cholesterol and triglyceride levels. In a Phase 1 trial, patients in the highest-dose group recorded reductions of up to 86 per cent in low-density lipoprotein (LDL) cholesterol and 82 per cent in triglycerides.

The results, though striking, come from a small number of patients in a dose-escalation study. Complete Phase 1 data will not be available until the second half of 2025, the company said.

CTX310 works by using the CRISPR-Cas9 system to disable the ANGPTL3 gene in the liver, which regulates fat metabolism. If proven safe and durable, the therapy could offer a new approach to treating cardiovascular risk, which is typically managed through lifelong use of statins or other drugs.

Until now, most CRISPR-based medicines have been developed for rare genetic disorders. By targeting common conditions such as high cholesterol, CRISPR Therapeutics is testing whether gene editing can extend beyond niche applications.

"This isn't niche innovation anymore," said one analyst. "This is a shot across the bow of chronic care itself."

Regulatory hurdles remain significant. Authorities will require extensive long-term safety data before approving a therapy that irreversibly alters DNA. Health insurers are also weighing how to price one-time treatments, with pressure to adopt value-based models that link reimbursement to outcomes. Scaling up manufacturing of gene-editing products presents further challenges.

For health systems, the potential benefits are considerable. A lasting therapy could reduce costs linked to medication adherence and repeated prescriptions. For patients, it could eliminate the burden of daily drug regimens.

Should CTX310 demonstrate consistent results in larger studies, it may force pharmaceutical groups to reconsider business models reliant on chronic therapies. For now, its promise remains unproven as testing continues.